339 related articles for article (PubMed ID: 2878748)
1. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E
Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
[TBL] [Abstract][Full Text] [Related]
2. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ; Liuzzi A
Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin analog treatment of acromegaly: new aspects.
Lamberts SW; del Pozo E
Horm Res; 1988; 29(2-3):115-7. PubMed ID: 2900190
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
5. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
van der Lely AJ; Harris AG; Lamberts SW
Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069
[TBL] [Abstract][Full Text] [Related]
6. A comparison between the effects of SMS 201-995, bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients.
Lamberts SW; Verleun T; Hofland L; Del Pozo E
Clin Endocrinol (Oxf); 1987 Jul; 27(1):11-23. PubMed ID: 2888550
[TBL] [Abstract][Full Text] [Related]
7. The effect of the somatostatin analog SMS 201-995 on normal growth hormone secretion in the rat. A comparison with the effect of bromocriptine on normal prolactin secretion.
Lamberts SW; Verleun T; Zuiderwijk JM; Oosterom R
Acta Endocrinol (Copenh); 1987 Jun; 115(2):196-202. PubMed ID: 2885995
[TBL] [Abstract][Full Text] [Related]
8. Effect of SMS 201-995, a long-acting somatostatin analogue, on the secretion and morphology of a pituitary growth hormone cell adenoma.
George SR; Kovacs K; Asa SL; Horvath E; Cross EG; Burrow GN
Clin Endocrinol (Oxf); 1987 Apr; 26(4):395-405. PubMed ID: 2888549
[TBL] [Abstract][Full Text] [Related]
9. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone-releasing factor increases serum prolactin concentrations in normal subjects and in patients with pituitary adenomas.
Serri O; Somma M; Rasio E; Brazeau P
Clin Endocrinol (Oxf); 1989 Jan; 30(1):65-75. PubMed ID: 2505955
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
12. A close correlation between the inhibitory effects of insulin-like growth factor-I and SMS 201-995 on growth hormone release by acromegalic pituitary tumours in vitro and in vivo.
Lamberts SW; van Koetsveld P; Hofland L
Clin Endocrinol (Oxf); 1989 Oct; 31(4):401-10. PubMed ID: 2627746
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
[TBL] [Abstract][Full Text] [Related]
14. Effect of a single administration of somatostatin analogue (SMS 201-995) on GH, TSH and insulin secretion in patients with acromegaly.
Horikawa R; Takano K; Hizuka N; Asakawa K; Shibasaki T; Masuda A; Shizume K
Endocrinol Jpn; 1986 Dec; 33(6):743-9. PubMed ID: 2884093
[TBL] [Abstract][Full Text] [Related]
15. Studies on the mechanism of action of the inhibitory effect of the somatostatin analog SMS 201-995 on the growth of the prolactin/adrenocorticotropin-secreting pituitary tumor 7315a.
Lamberts SW; Reubi JC; Uiterlinden P; Zuiderwijk J; van den Werff P; van Hal P
Endocrinology; 1986 Jun; 118(6):2188-94. PubMed ID: 2870915
[TBL] [Abstract][Full Text] [Related]
16. Serum prolactin and growth hormone response to thyrotropin-releasing hormone in patients with pituitary adenomas.
Chang CC; Chen FW; Hsieh HC
Taiwan Yi Xue Hui Za Zhi; 1989 May; 88(5):443-9. PubMed ID: 2507734
[TBL] [Abstract][Full Text] [Related]
17. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly.
Plewe G; Beyer J; Krause U; Neufeld M; del Pozo E
Lancet; 1984 Oct; 2(8406):782-4. PubMed ID: 6148524
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone releasing factor induces prolactin secretion in acromegalic patients but not in normal subjects.
Losa M; Schopohl J; Müller OA; von Werder K
Acta Endocrinol (Copenh); 1985 Aug; 109(4):467-73. PubMed ID: 3929513
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone releasing factor stimulates and somatostatin inhibits prolactin release from human mixed somatotroph-lactotroph adenomas in perifusion.
Serri O
Clin Endocrinol (Oxf); 1987 Dec; 27(6):675-82. PubMed ID: 2901301
[TBL] [Abstract][Full Text] [Related]
20. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]